Earnings
Legal firms are lining up to lead litigation against the company on behalf of shareholders who saw their stock dive.
With the acquisition of the Roche stake, SoftBank has become one of the company’s biggest stakeholders.
Schrödinger and Zai Lab have announced a worldwide development and commercialization collaboration to advance a novel oncology program targeting the DNA damage repair pathway.
Shares of Zymergen plummeted by 68% Tuesday from its April IPO price of $31 per share to just $11.7 per share after news that the company will not likely see revenue anytime soon.
Eli Lilly and Company is in the news with positive Olumiant data in COVID-19, a drop in COVID-19 product sales for the quarter and a protest of one of their ads. Here’s a look.
The company saw global net revenue of $13.9 billion during the second quarter, an increase of 33.9%. Sales were primarily driven by its immunology portfolio, which generated $6.12 billion.
As Gilead gets ready to open its doors to its new operations site in North Carolina, the company reported its product sales for the second quarter increased 21% year-over-year primarily driven by Veklury.
The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.
Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.
Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.
PRESS RELEASES